Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 10th Sep 2013 08:17

African Barrick Gold: Investec shifts target price from 135p to 137p, while downgrading from hold to sell.Aquarius Platinum: JP Morgan moves target price from 39p to 49p, while downgrading from neutral to underweight. Citi lowers target price from 66p to 54p and downgrades from buy to neutral.AstraZeneca: Jefferies reduces target price from 3400p to 3200p, while keeping its hold recommendation.Barclays: Alphavalue shifts target price from 342.10p to 341.70p downgrading from buy to add.Betfair: Deutsche Bank raises target price from 884p to 945p staying with its hold recommendation. Citi takes target price from 975p to 1150p and reiterates a buy recommendation.BG Group: Morgan Stanley cuts target price from 1400p to 1370p and retains an overweight rating.Billington Holdings: WH Ireland raises target price from 70p to 125p and maintains a buy recommendation.British Sky Broadcasting: Goldman Sachs ups target price from 1010p to 1170p and reiterates a strong buy recommendation.Centamin: Investec moves target price from 45.60p to 50p keeping its buy recommendation.Craneware: Investec places both its target price (prev.: 365p) and its buy recommendation under review. N+1 Singer downgrades to hold with a target price of 375p.Daily Mail & General Trust: Goldman Sachs raises target price from 695p to 780p, but still recommends selling.Darty: Alphavalue shifts target price from 73.20p to 73.80p and upgrades from sell to reduce.Eland Oil & Gas: Canaccord Genuity lowers target price from 180p to 173p, while leaving its buy recommendation unchanged.Evraz: JP Morgan reduces target price from 252p to 116p keeping its underweight rating.Fenner: Investec ups target price from 330p to 370p and stays with its hold recommendation.GlaxoSmithKline: Jefferies cuts target price from 1825p to 1800p maintaining a hold recommendation.Hilton Food Group: Investec placet both its target price (prev.: 352p) and its add rating under review. Panmure Gordon ups target price from 450p to 480p and keeps a buy recommendation.IGas Energy: Canaccord Genuity moves target price from 174p to 181p retaining a buy recommendation.Intertek Group: Deutsche Bank increases target price from 2820p to 3243p reiterating a hold recommendation.ISG: WH Ireland moves target price from 240p to 250p and reiterates its buy recommendation.Ithaca Energy: Liberum Capital initiates with a target price of 210p and a buy recommendation.Lonmin: JP Morgan takes target price from 330p to 400p and maintains an overweight rating. Citi ups target price from 374p to 418p keeping a buy recommendation.Moneysupermarket: Westhouse Securities downgrades to add with a target price of 195p.Oxford Instruments: Investec ups target price from 1320p to 1500p, while its hold recommendation remains unaltered.Randgold Resources: Investec increases target price from 4981p to 5018p leaving its hold recommendation unchanged.Regus: Panmure Gordon takes target price from 200p to 250p and stays with its buy recommendation.Rio Tinto: JP Morgan raises target price from 4200p to 4300p reiterating an overweight rating.SABMiller: HSBC increases target price from 3400p to 3600p upgrading to overweight.SSE: Morgan Stanley ups target price from 1185p to 1280p, while leaving its underweight rating unchanged.Surgical Innovations: Panmure Gordon shifts target price from 6.60p to 7.60p, while its buy recommendation remains unaltered.Unilever: Deutsche Bank raises target price from 2590p to 2800p upgrading to buy.WPP Group: Goldman Sachs increases target price from 1340p to 1600p and keeps a buy recommendation. Berenberg ups target price from 1050p to 1085p, but still recommends selling.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.